Dr. Coyle Named Chief Scientific Advisor

In the interview, Dr. Coyle explains the new frontier of neuropsychiatric research and how SyneuRx is taking up this challenging task.

Aug 07, 2022

Media - verywellmind

July 25, 2022

Press Release

July 05, 2022

Media - Eat This Not That

May 27, 2022

Media - Eat This Not That

Online article contributed by Dr. Tsai: “Virus Expert Says “Be Ready for This to Happen Next” — A new big wave of infection is coming to the U.S.”

SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® completed US Phase 2 clinical trial in June 2022 (click here for trial information). The Phase 3 study is expected to be launched in late 2022 as a global multi-center clinical trial. First-in-human study for Airnecflu® is expected to launch in the second half of 2022.
Pentarlandir for COVID-19 (Oral Antiviral)
Phase 2
Airneclfu for COVID-19 (Inhaler)
Phase 1
NaBen for Adult Schizophrenia
Phase 2/3
ClozaBen for Refractory Schizophrenia
Phase 2/3
NaBen for Adolescent Schizophrenia
Phase 2/3
NaBen for Early Dementia
Phase 2/3
Tannquilynne for Dementia & Psychosis
Phase 2
Synapsinae for Depression and Suicidality
Phase 3
Synxyrin for Treatment Resistant Depression
Phase 2



SNB01 COVID-19 Antiviral

Enrollment Complete
Learn More
snd12a-300x300 copy



SND13 Adult Schizophrenia

Learn More
SND13a-300x300 copy


Refractory Schizophrenia

SND12 Refractory Schizophrenia

Learn More
SND13-291x300 copy


Adolescent Schizophrenia

SND11 Adolescent Schizophrenia

Learn More